Literature DB >> 9310073

The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test.

K De Ore1, N H Greig, H W Holloway, Y Wang, R Perfetti, J M Egan.   

Abstract

Glucose intolerance is a common feature of the aging process, and aging per se is an etiologic factor for Type II diabetes mellitus. To characterize the beta cell abnormalities that occur with aging, we looked at the serum glucose and insulin levels of six young (3-month) and six old (22-month) Wistar rats at 0, 2, 4, 7, 10, 15, 20, and 30 minutes after an intravenous glucose load (IVGTT, 0.5 g/kg glucose). We found that the fasting glucose and insulin levels were not significantly different between young and old rats. However, peak glucose levels were significantly higher in the old (349 +/- 10 mg/dl) compared to the young (250 +/- 7 mg/dl) animals (p < .0001). Insulin levels in the young animals peaked at 2 minutes (859 +/- 171 pmol/l) with a quick return toward fasting levels by 7 minutes. The old animals had a delayed and blunted insulin response to glucose, achieving lower peak insulin levels (656 +/- 164 pmol/l) 7 minutes after the glucose load. As insulin levels are also positively modulated by incretin hormones, we quantitated the fasting insulin responses of young and old animals to .05, 0.1, 0.2, 0.4, and 0.5 nmol/kg intravenous glucagon-like peptide-1 (GLP-1), the most potent incretin known. Insulin responses were similar in both age groups, with maximum insulin responses seen at 0.4 nmol/kg. GLP-1, in conjunction with the IVGTT, restored the acute insulin response to glucose and increased the clearance of glucose in the old animals. It therefore appears that old animals have an impaired glucose-mediated insulin release but maintain their insulin responsivity to GLP-1. This makes it a likely candidate in the treatment of Type II diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310073     DOI: 10.1093/gerona/52a.5.b245

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  5 in total

1.  Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.

Authors:  Hui Min Chan; Ritesh Jain; Bo Ahrén; Giovanni Pacini; David Z D'Argenio
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-02-09       Impact factor: 3.619

2.  Baroreflex function and postprandial hypotension in older adults.

Authors:  Kenneth M Madden; Boris Feldman; Graydon S Meneilly
Journal:  Clin Auton Res       Date:  2020-02-15       Impact factor: 4.435

3.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

4.  Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects.

Authors:  Rongrong Fan; Zhanfang Kang; Lan He; Juliana Chan; Gang Xu
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

Review 5.  Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases.

Authors:  Wei Peng; Rui Zhou; Ze-Fang Sun; Jia-Wei Long; Yong-Qiang Gong
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.